Mirna Therapeutics, Inc. (NASDAQ:SYBX) – Analysts at Leerink Swann issued their FY2017 earnings estimates for shares of Mirna Therapeutics in a report issued on Tuesday. Leerink Swann analyst J. Schwartz expects that the biotechnology company will earn ($3.20) per share for the year. Leerink Swann currently has a “Outperform” rating and a $25.00 target price on the stock. Leerink Swann also issued estimates for Mirna Therapeutics’ FY2018 earnings at ($1.50) EPS and FY2019 earnings at ($1.70) EPS.

TRADEMARK VIOLATION NOTICE: This piece was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2017/09/23/leerink-swann-weighs-in-on-mirna-therapeutics-inc-s-fy2017-earnings-sybx.html.

Separately, ValuEngine lowered shares of Mirna Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $15.44.

Shares of Mirna Therapeutics (NASDAQ SYBX) opened at 18.15 on Thursday. The firm’s market cap is $295.52 million. The company’s 50-day moving average is $12.11 and its 200-day moving average is $12.91. Mirna Therapeutics has a 52 week low of $7.84 and a 52 week high of $23.00.

Mirna Therapeutics Company Profile

Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).

Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.